Marta Llanos

First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study

Eduardo Díaz‐Rubio, Auxiliadora Gómez‐España, Bartomeu Massutí et al. · The Oncologist · 2012 · 212 citations · Full text

LEPTIN ROLE IN ADVANCED LUNG CANCER. A MEDIATOR OF THE ACUTE PHASE RESPONSE OR A MARKER OF THE STATUS OF NUTRITION?

María Remedios Alemán Valls, Francisco Santolaria, Norberto Batista et al. · Cytokine · 2002 · 116 citations

A Mediator, Medicine, Immunology +5

Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: A phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801)

Daniel Castellano, Jaume Capdevila, Javier Sastre et al. · European Journal of Cancer · 2013 · 97 citations

Bevacizumab Combination, Oncology, Medicine +9

Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE)

Barbara Nuñez-Valdovinos, Alberto Carmona‐Bayonas, Paula Jiménez‐Fonseca et al. · The Oncologist · 2018 · 90 citations · Full text

Prognostic Significance of Ki-67 Nuclear Proliferative Antigen, bcl-2 Protein, and p53 Expression in Follicular and Diffuse Large B-Cell Lymphoma

Marta Llanos, Hugo Álvarez‐Argüelles, R.M. García Alemán et al. · Medical Oncology · 2001 · 79 citations

Hematological Malignancy, Tumor Biology, Lymphoid Neoplasia +9